JP2020511455A5 - - Google Patents

Download PDF

Info

Publication number
JP2020511455A5
JP2020511455A5 JP2019549417A JP2019549417A JP2020511455A5 JP 2020511455 A5 JP2020511455 A5 JP 2020511455A5 JP 2019549417 A JP2019549417 A JP 2019549417A JP 2019549417 A JP2019549417 A JP 2019549417A JP 2020511455 A5 JP2020511455 A5 JP 2020511455A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
oxazepam
metyrapone
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019549417A
Other languages
English (en)
Japanese (ja)
Other versions
JP7048629B2 (ja
JP2020511455A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/021939 external-priority patent/WO2018165649A1/en
Publication of JP2020511455A publication Critical patent/JP2020511455A/ja
Publication of JP2020511455A5 publication Critical patent/JP2020511455A5/ja
Application granted granted Critical
Publication of JP7048629B2 publication Critical patent/JP7048629B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019549417A 2017-03-10 2018-03-12 医薬組成物およびその使用 Expired - Fee Related JP7048629B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762469798P 2017-03-10 2017-03-10
US62/469,798 2017-03-10
PCT/US2018/021939 WO2018165649A1 (en) 2017-03-10 2018-03-12 Pharmaceutical compositions and uses thereof

Publications (3)

Publication Number Publication Date
JP2020511455A JP2020511455A (ja) 2020-04-16
JP2020511455A5 true JP2020511455A5 (https=) 2021-04-22
JP7048629B2 JP7048629B2 (ja) 2022-04-05

Family

ID=63449154

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019549417A Expired - Fee Related JP7048629B2 (ja) 2017-03-10 2018-03-12 医薬組成物およびその使用

Country Status (9)

Country Link
US (1) US11179377B2 (https=)
EP (1) EP3592350B1 (https=)
JP (1) JP7048629B2 (https=)
CN (1) CN110582278B (https=)
AU (1) AU2018230521B2 (https=)
BR (1) BR112019018700A2 (https=)
CA (1) CA3055940A1 (https=)
EA (1) EA201992142A1 (https=)
WO (1) WO2018165649A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230018445A (ko) * 2020-06-02 2023-02-07 알.피.쉐러 테크놀러지즈 엘엘씨 지연 방출 소프트겔 캡슐
CN119606886B (zh) * 2025-01-09 2025-10-17 成都苑东生物制药股份有限公司 一种奥沙西泮的药物组合物

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0081913B1 (en) * 1981-12-11 1985-06-26 JOHN WYETH & BROTHER LIMITED Process and apparatus for freezing a liquid medium
US4942162A (en) 1982-03-31 1990-07-17 University Of Tennessee Research Corporation Topical treatment of seborrheic dermatitis with ketoconazole
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
US4594329A (en) 1984-05-14 1986-06-10 The Salk Institute For Biological Studies CRF analogs
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4661493A (en) 1985-03-29 1987-04-28 Pfizer Inc. Tioconazole and related compounds for control of Herpes simplex virus
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5016655A (en) 1986-10-21 1991-05-21 C.A. Blockers, Inc. Cigarette manufacturing process
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US4814333A (en) 1987-07-28 1989-03-21 The Trustees Of Dartmouth College Method for treatment of hypercortisolemic, depressed patients
US4925844A (en) 1988-02-09 1990-05-15 Ici Americas Inc. Antagonizing the pharmacological effects of a benzodiazepine receptor agonist
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
DE3842007A1 (de) 1988-12-14 1990-06-21 Henkel Kgaa Fluessiges bis pastoeses, bleichmittelhaltiges waschmittel
US4974729A (en) 1989-04-17 1990-12-04 Bristol-Myers Squibb Company Reminder system for taking medication
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US5008528A (en) 1989-07-14 1991-04-16 Logitech S.A. Invertible trackball
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
ATE352612T1 (de) 1990-08-29 2007-02-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
US20050090553A1 (en) 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US6326463B1 (en) 1994-12-12 2001-12-04 The Salk Institute For Biological Studies Cyclic CRF agonists
US6323312B1 (en) 1994-12-12 2001-11-27 The Salk Institute For Biological Studies Cyclic CRF antagonist peptides
US20030211157A1 (en) 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US5869474A (en) 1997-05-16 1999-02-09 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Low dosage treatment for cocaine craving and withdrawal
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
NZ334627A (en) 1999-03-12 2002-07-26 Horticulture & Food Res Inst A therapeutic composition containing a therapeutic agent such as an anthelmintic and an antistress agent such as metyrapone or a nitric oxide promoter for increasing efficacy of therapeutic agents and animal growth
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
GB0001449D0 (en) 2000-01-21 2000-03-08 Cortendo Ab Compositions
US6630449B2 (en) 2000-12-21 2003-10-07 David Wastchak Method for reducing the effect of nicotine addiction and dependancy
AU2002322475B2 (en) 2001-06-26 2008-02-21 North Carolina State University Blocking peptide for inflammatory cell secretion
GB0205253D0 (en) 2002-03-06 2002-04-17 Univ Gent Immediate release pharmaceutical granule compositions and a continuous process for making them
EP1523310A2 (en) 2002-07-09 2005-04-20 The Scripps Research Institute Method to inhibit ischemia and reperfusion injury
KR100503889B1 (ko) 2002-07-20 2005-07-26 한국과학기술연구원 옥틸로늄 브로마이드를 함유하는 항암제 흡수 증진제
AU2003268026A1 (en) 2002-07-30 2004-02-16 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
US20040067986A1 (en) 2002-10-04 2004-04-08 Nathan Sassover Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer
US20050037983A1 (en) 2003-03-11 2005-02-17 Timothy Dinan Compositions and methods for the treatment of depression and other affective disorders
US20040185170A1 (en) * 2003-03-21 2004-09-23 Shubha Chungi Method for coating drug-containing particles and formulations and dosage units formed therefrom
US20080206138A1 (en) 2003-08-06 2008-08-28 Ilse Zolle Radiolabelled Phenylethyl Imidazole Carboxylic Acid Ester Derivatives
MXPA06002618A (es) 2003-09-09 2006-06-05 Ono Pharmaceutical Co Antagonistas del factor de liberacion de corticotropina (crf) y compuestos heterobiciclicos.
US20050203130A1 (en) 2003-12-02 2005-09-15 Erik Buntinx Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
WO2005061508A1 (ja) 2003-12-22 2005-07-07 Ono Pharmaceutical Co., Ltd. 三環式複素環化合物およびその化合物を有効成分とする医薬
JP4399593B2 (ja) 2004-04-01 2010-01-20 国立大学法人 千葉大学 インフルエンザ脳症の検査法、及び、ヒト髄液中に発現するタンパク質からなるマーカ、診断薬、診断キット
CA2568159A1 (en) 2004-05-28 2005-12-15 Speedel Experimenta Ag Tetrahydro-imidazo [1,5-a] pyridin derivatives as aldosterone synthase inhibitors
CN1997643A (zh) 2004-05-28 2007-07-11 斯皮德尔实验股份公司 杂环化合物及其作为醛固酮合酶抑制剂的应用
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
US9415107B2 (en) 2005-11-10 2016-08-16 Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College Compositions and methods for the treatment of addiction and other neuropsychiatric disorders
CA2643802A1 (en) 2006-02-27 2007-09-07 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
WO2007117982A2 (en) 2006-03-29 2007-10-18 Novartis Ag Organic compounds
EP2094680A2 (en) 2006-12-18 2009-09-02 Novartis AG Imidazoles as aldosterone synthase inhibitors
US20080152709A1 (en) 2006-12-22 2008-06-26 Drugtech Corporation Clonidine composition and method of use
US8318813B2 (en) 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
US8475823B2 (en) 2008-04-18 2013-07-02 Medtronic, Inc. Baclofen formulation in a polyorthoester carrier
DE102008022221A1 (de) 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
US8771735B2 (en) 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
EP2430011A1 (en) 2009-05-15 2012-03-21 Novartis AG 5-pyridin-3-yl-1,3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or cyp11b1
HRP20140371T1 (hr) 2009-05-15 2014-05-23 Novartis Ag Arilpiridini kao inhibitori sinteze aldosterona
WO2010130773A2 (en) 2009-05-15 2010-11-18 Novartis Ag Benzoxazolone derivatives as aldosterone symthase inhibitors
US8541404B2 (en) 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
US8519134B2 (en) 2009-11-17 2013-08-27 Novartis Ag Aryl-pyridine derivatives as aldosterone synthase inhibitors
WO2011064769A1 (en) 2009-11-24 2011-06-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and pharmaceutical compositions for the treatment of hot flashes
ES2472446T3 (es) 2009-11-30 2014-07-01 Novartis Ag Derivados de imidazol como inhibidores de aldosterona sintasa
HUE041967T2 (hu) 2010-01-14 2019-06-28 Novartis Ag Mellékvese hormon-módosító szer alkalmazása
EP2582375A4 (en) * 2010-06-16 2013-12-25 Embera Neurotherapeutics Inc COMPOSITIONS AND METHODS FOR TREATMENT OF ADDICTION, PSYCHIATRIC DISORDERS, AND NEURODEGENERATIVE DISEASE
US20120237482A1 (en) 2011-03-18 2012-09-20 Juan Rodriguez Methods for treatment of neurological disorders by modulation of microglial activation
EP2841595A2 (en) 2012-04-23 2015-03-04 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Genetic predictors of response to treatment with crhr1 antagonists
EP2961390A1 (en) 2013-03-01 2016-01-06 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical formulations comprising quetiapine and escitalopram
KR20160026897A (ko) 2013-06-27 2016-03-09 세다르스-신나이 메디칼 센터 신경퇴행성 질환의 예방 및 치료를 위한 아드레날린 수용체 길항제
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
CN104288385A (zh) 2014-10-23 2015-01-21 朱道明 一种戒毒中药
CN108025008A (zh) 2015-06-22 2018-05-11 安比拉神经疗法公司 用于治疗物质使用障碍、成瘾和精神病的组合物和方法
WO2017023694A1 (en) 2015-08-03 2017-02-09 Pop Test Oncology Llc Pharmaceutical compositions and methods
WO2017143034A1 (en) 2016-02-16 2017-08-24 Embera Neurotherapeutics, Inc. Compositions and methods for treating substance abuse disorders
EP3423063A4 (en) 2016-03-04 2019-11-06 Embera Neurotherapeutics, Inc COMPOSITIONS AND METHODS FOR TREATING SEARCH OR SUBSTANCE ABUSE MISTAKES
WO2018213713A1 (en) 2017-05-19 2018-11-22 Embera Neurotherapeutics, Inc. Compositions and methods for the treatment of addiction, psychiatric disorders, and neurodegenerative disease

Similar Documents

Publication Publication Date Title
TWI504419B (zh) 層狀醫藥調配物
CN102740854A (zh) 含有洛索洛芬的医药组合物
CZ20002198A3 (cs) Prostředek k léčbě respiračních a kožních onemocnění, který obsahuje alespoň jednoho antagonistu leukotrienu a alespoň jedno antihistaminikum
RU2016125229A (ru) Комбинированная система доставки с немедленным/замедленным высвобождением для лекарственных средств с коротким периодом полувыведения, в том числе для ремоглифлозина
CN121622680A (zh) 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法
AU2011261118A1 (en) Multi phase soft gel capsules, apparatus and method thereof
JP2012158592A5 (https=)
JP2013511507A5 (https=)
JP2009517466A5 (https=)
CN105431144A (zh) 阿坎酸制剂、使用阿坎酸制剂的方法以及包含阿坎酸制剂的组合
US20200368216A1 (en) Treatment of sunburn using analgesics and antihistamines
TW201106991A (en) Tablets
EP2200590A1 (en) Composition and method of stabilized sensitive ingredient
TW201110968A (en) A thrombin receptor antagonist and clopidogrel fixed dose tablet
JP2020511455A5 (https=)
CN101015519B (zh) 一种氯雷他定口服复方药物组合物
CN104379138A (zh) 阿坎酸制剂、其使用方法及包含阿坎酸制剂的组合
CN102920707A (zh) 一种复方抗结核制剂的制备工艺
JP7274288B2 (ja) 医薬品
JP2020510103A (ja) 多発性硬化症を処置するための組成物および方法
US20240293329A1 (en) Pharmaceutically stable soft capsule comprising two or more different compositions
CN101756935A (zh) 一种奥美拉唑胶囊及其制备方法
CN117136048A (zh) 用于治疗由毒蕈碱受体激活所缓解的障碍的方法
JP2017515858A5 (https=)
JP2007513095A5 (https=)